埃沃胺-葡萄糖结合物的设计具有改善的活体抗瘤活性
Zhe Wu1, Shuqiang Chen2, Zhipeng Chen2
1School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou 213164, People's Republic of China.
Journal of medicinal chemistry
|April 22, 2024
概括
乙胺-葡萄糖合物通过向葡萄糖载体-1 (GLUT1) 来提高水溶性和抗瘤功效. 这种方法降低了正常细胞的毒性,并显示出作为新型癌症治疗药物的潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 埃沃迪胺是一种天然产品,表现出多重向抗瘤活性,但具有较差的溶解性和有限的体内活性.
- 埃沃胺衍生物的临床开发受到水溶性差以及体内抗瘤效果不足的阻碍.
研究的目的:
- 设计和合成埃沃胺-葡萄糖合物,以提高水溶性和体内抗瘤功效.
- 研究这些结合物的潜力,以向葡萄糖载体-1 (GLUT1) 进行选择性癌症治疗.
主要方法:
- 一系列埃沃胺-葡萄糖合物的合成.
- 对结合物的水溶性,体内抗瘤功效和细胞毒性进行评估.
- 研究抗瘤机制,包括Top1/Top2抑制,亡诱导和细胞循环停止.
主要成果:
- 与原始化合物相比,合物8显著提高了水溶性和体内抗瘤功效.
- GLUT1向导致对正常细胞的细胞毒性降低.
- 结合剂8通过双重Top1/Top2抑制,亡诱导和G2/M细胞周期停止,选择性地向GLUT1表达瘤细胞.
结论:
- 乙胺-葡萄糖合物是克服乙胺在癌症治疗中的局限性的有希望的策略.
- 结合剂8具有强大和选择性的抗瘤活性,突出显示其作为新型治疗剂的潜力.
相关概念视频
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176


